Journal
Leukemia & Lymphoma
Publication Date
10-1-2025
Volume
66
Issue
10
First Page
1903
Last Page
1912
Document Type
Open Access Publication
DOI
10.1080/10428194.2025.2525982
Rights and Permissions
Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL. Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201. Leuk Lymphoma. 2025 Oct;66(10):1903-1912. doi: 10.1080/10428194.2025.2525982. © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Recommended Citation
Andreadis, Charalambos; Kahl, Brad S; Bartlett, Nancy L; and et al., "Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: Primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201." Leukemia & Lymphoma. 66, 10. 1903 - 1912. (2025).
https://digitalcommons.wustl.edu/oa_4/5734
Additional Links
Supplemental material is available for this article at publisher site.
